Literature DB >> 21744385

The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project.

A Wimo1, L Jönsson, A Gustavsson, D McDaid, K Ersek, J Georges, L Gulácsi, K Karpati, P Kenigsberg, H Valtonen.   

Abstract

OBJECTIVE: Care for demented people is very resource demanding, the prevalence is increasing and there is so far no cure. Cost of illness (CoI) studies are important by identifying the distribution of costs between different payers of care. The European Union (EU) funded the European Collaboration on Dementia (Eurocode) as part of the EU's 2005 work plan of the Community public health programme. Eurocode was administered by Alzheimer Europe. The aim was to describe the economic impact of dementia in Europe in 2008.
METHODS: Eurocode's new estimates for dementia prevalence were included in a cost model based on published European CoI papers. For countries where no CoI figures were available, imputation was used.
RESULTS: The total CoI of dementia in the EU27 in 2008 was estimated to be €160 billion (€22 000 per demented per year), of which 56% were costs of informal care. The corresponding costs for the whole Europe was €177 billion. In northern Europe, the direct costs are estimated to be considerabe, while the cost of informal care is the major cost component in southern Europe. The sensitivity analysis showed a range for total EU27 costs between €111 and 168 billion.
CONCLUSIONS: The estimated CoI in this study is higher than in previous studies. There are also large differences in different European regions. Notwithstanding the methodological challenges, the societal costs of dementia in Europe are very high which in turn have substantial resource impacts on the social and health care systems in Europe.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21744385     DOI: 10.1002/gps.2610

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  42 in total

1.  Stress-Induced Alterations of Immune Profile in Animals Suffering by Tau Protein-Driven Neurodegeneration.

Authors:  Petr Novak; Martin Cente; Nina Kosikova; Tomas Augustin; Richard Kvetnansky; Michal Novak; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2017-04-12       Impact factor: 5.046

2.  Neuroprotective effects of digested polyphenols from wild blackberry species.

Authors:  Lucélia Tavares; Inês Figueira; Gordon J McDougall; Helena L A Vieira; Derek Stewart; Paula M Alves; Ricardo B Ferreira; Cláudia N Santos
Journal:  Eur J Nutr       Date:  2013-02       Impact factor: 5.614

Review 3.  Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.

Authors:  Irene Bolea; Alejandro Gella; Mercedes Unzeta
Journal:  J Neural Transm (Vienna)       Date:  2012-12-13       Impact factor: 3.575

4.  Synthesis of novel 7-aryl and 7-spiropyrazolo[4',3':5,6]pyrido[2,3-d]pyrimidine derivatives and their study as AChE inhibitors.

Authors:  Paola Acosta; Braulio Insuasty; Rodrigo Abonia; Margarita Gutierrez; Jairo Quiroga
Journal:  Mol Divers       Date:  2017-08-07       Impact factor: 2.943

5.  Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease.

Authors:  Scott E Counts; Shaoli Che; Stephen D Ginsberg; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2011-03-17       Impact factor: 3.052

6.  Progressive and unconventional pharmacotherapeutic approaches to Alzheimer's disease therapy.

Authors:  Stuart Maudsley; Wayne Chadwick
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

Review 7.  Diagnosis and management of the patient with suspected dementia in primary care.

Authors:  Stefan Holzer; James P Warner; Steve Iliffe
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

8.  Predictors of progression to severe Alzheimer's disease in an incidence sample.

Authors:  Peter V Rabins; Sarah Schwartz; Betty S Black; Christopher Corcoran; Elizabeth Fauth; Michele Mielke; Jessica Christensen; Constantine Lyketsos; Joann Tschanz
Journal:  Alzheimers Dement       Date:  2012-11-02       Impact factor: 21.566

Review 9.  Silent cerebral infarcts associated with cardiac disease and procedures.

Authors:  Mariëlla E C Hassell; Robin Nijveldt; Yvo B W Roos; Charles B L Majoie; Martial Hamon; Jan J Piek; Ronak Delewi
Journal:  Nat Rev Cardiol       Date:  2013-10-29       Impact factor: 32.419

10.  Mildronate improves cognition and reduces amyloid-β pathology in transgenic Alzheimer's disease mice.

Authors:  Ulrika Beitnere; Thomas van Groen; Ashish Kumar; Baiba Jansone; Vija Klusa; Inga Kadish
Journal:  J Neurosci Res       Date:  2013-11-22       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.